Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017

Dec 20 2011

• By Wendy Diller

Related Content

Biogen Tests Biosimilars Waters In Joint Venture With Samsung

Dec 12 2011

And Now For The <i>Real</i> Biosimilar Opportunity: Antibodies And Complex Biologics

Jun 27 2011

In One Day, Change At Biotechs: Leiden To Replace Emmens At Vertex And At Amgen, Bradway Will Become CEO

Dec 15 2011

Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says

Dec 14 2011

Biosimilars: A New Kind Of Innovation

Nov 30 2011

Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?

Nov 07 2011

Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics

Dec 05 2011

Related Companies

Amgen, Inc.

Allergan plc

Roche Holding AG

Eli Lilly and Company

Novartis AG

Novartis AG

Teva Pharmaceutical Industries Ltd.

Hospira, Inc.

Lonza Group AG

Celltrion, Inc.

Viatris Inc.

Biocon, Ltd.

Biogen, Inc.

Merck KGaA

Additional Topics

United States Asia Pacific Strategy Business Strategies Advertising, Marketing & Sales Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window